

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
May 07, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 7, 2013

**Keryx Biopharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction

of Incorporation)

000-30929  
(Commission

File Number)

13-4087132  
(IRS Employer

Identification No.)

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**750 Lexington Avenue**

**New York, New York 10022**

**(Address of Principal Executive Offices)**

**(212) 531-5965**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  
- .. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On May 7, 2013, Keryx Biopharmaceuticals, Inc. ( Keryx ) issued a press release announcing its results of operations for the first quarter ended March 31, 2013. Keryx also announced that on Wednesday, May 8, 2013 at 8:30am EDT, Keryx will host an investor conference call to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2013. A copy of such press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**

(Registrant)

Date: May 7, 2013

By: /s/ James F. Oliviero  
James F. Oliviero, CFA  
Chief Financial Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated May 7, 2013.